ACT-1014-6470

ACT-1014-6470 is an orally active, potent, reversible, and selective C5aR1 antagonist. ACT-1014-6470 demonstrates potent inhibition of C5aR1 activation. ACT-1014-6470 can be used in the research of inflammatory diseases[1][2].

Product Specifications

CAS Number

[2363082-87-3]

UNSPSC

12352005

Target

Complement System

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

O=C1N(CC2=CC=CC=C2C(F)(F)F)C3=NN(CC(F)(F)C)C=C3CN1C4CCN(C5=C(C)C=CC=C5F)CC4

Molecular Formula

C28H29F6N5O

Molecular Weight

565.55

References & Citations

[1]Sylvie FROIDEVAUX, et al. 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases. WO2019137927A1. WIPO (PCT) . 2019-01-09. |[2]Ort M, et al. First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients. Basic Clin Pharmacol Toxicol. 2022 Aug;131 (2) :114-128.